Kyohei Misawa Hajime Yasuda Hironari Matsuda Munechika Hara Tomonori Ochiai Daisuke Koyama Hina Takano Noriaki Iwao Michiaki Koike
10.2169/internalmedicine.9405-22
Intern Med
2022;61(22):3421-3424.
adult t cell leukemia/lymphoma human t-cell leukemia virus-1 hyperprogressive disease immune checkpoint inhibitors nivolumab
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/36385048/
Carcinoma, Non-Small-Cell Lung / therapy Leukemia-Lymphoma, Adult T-Cell / drug therapy Lung Neoplasms / therapy
Carcinoma, Non-Small-Cell Lung / therapy Leukemia-Lymphoma, Adult T-Cell / drug therapy Lung Neoplasms / therapy Case Reports Humans Nivolumab / adverse effects Programmed Cell Death 1 Receptor Programmed Cell Death 1 Receptor Nivolumab
PMC9751725
36385048
Development of Acute Adult T-cell Leukemia Following PD-1 Blockade Therapy for Lung Cancer
2022